STORM, Therapeutics

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

Published on 08/07/2025 at 18:05 | prnewswire.co.uk

STORM Therapeutics England Texas

View original content:https://www.prnewswire.co.uk/news-releases/storm-therapeutics-to-present-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024-302154468.html

en | boerse | 67964241 |